Together, these studies indicate that ER+ breast cancers generally contain fewer immune cells, particularly CD8+ cytotoxic T cells, and suggest that the frequency of immune subpopulations with high prognostic value for other cancer types, including TNBC, are less valuable for ER+ cancers. The gene discussed is CD8A; the disease is cancer.